LIPO - Lipella Pharmaceuticals Inc. Stock Price, Fair Value and News

0.73USD0.00 (0.00%)Market Closed

Market Summary

USD0.730.00

Market Closed

0.00%

LIPO Stock Price

View Fullscreen

LIPO RSI Chart

LIPO Valuation

Market Cap

4.6M

Price/Earnings (Trailing)

-0.99

Price/Sales (Trailing)

10.15

EV/EBITDA

-0.28

Price/Free Cashflow

-1.44

LIPO Price/Sales (Trailing)

LIPO Profitability

EBT Margin

-1027.31%

Return on Equity

-146.89%

Return on Assets

-129.12%

Free Cashflow Yield

-69.36%

LIPO Fundamentals

LIPO Revenue

Revenue (TTM)

449.6K

Rev. Growth (Yr)

-19.98%

Rev. Growth (Qtr)

16.14%

LIPO Earnings

Earnings (TTM)

-4.6M

Earnings Growth (Yr)

-89.29%

Earnings Growth (Qtr)

47.95%

Breaking Down LIPO Revenue

Last 7 days

1.4%

Last 30 days

5.8%

Last 90 days

-27%

How does LIPO drawdown profile look like?

LIPO Financial Health

Current Ratio

8.9

LIPO Investor Care

Shares Dilution (1Y)

47.04%

Diluted EPS (TTM)

-0.78

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	269.1K	375.7K	479.8K	449.6K
2022	240.5K	221.8K	203.0K	184.2K
2021	0	0	0	259.3K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Lipella Pharmaceuticals Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 19, 2024	kaufman jonathan h	bought	21,802	0.8721	25,000	see remarks below.
Mar 18, 2024	kaufman jonathan h	bought	23,649	0.7883	30,000	see remarks below.
Mar 13, 2024	kaufman jonathan h	acquired	99,999	0.6901	144,906	see remarks below.
Mar 13, 2024	chancellor michael b	acquired	99,999	0.6901	144,906	chief medical officer
Dec 22, 2022	chancellor michael b	acquired	131,962	5.75	22,950	chief medical officer

Which funds bought or sold LIPO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	-16,573	35,210	-%
Feb 14, 2024	TWO SIGMA INVESTMENTS, LP	new	-	16,182	16,182	-%
Feb 14, 2024	SABBY MANAGEMENT, LLC	new	-	275,226,000	275,226,000	0.28%
Feb 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	new	-	42,931	42,931	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	added	40.63	-323	7,057	-%
Feb 09, 2024	UBS Group AG	added	342	518	776	-%
Feb 09, 2024	WELLS FARGO & COMPANY/MN	added	3.57	-12.00	30.00	-%
Feb 07, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%

Are Funds Buying or Selling LIPO?

Are funds buying LIPO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LIPO

No. of Funds

Unveiling Lipella Pharmaceuticals Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 19, 2024	kaufman jonathan h	21.0%	1,635,015	SC 13D/A
Mar 15, 2024	kaufman jonathan h	19.5%	1,500,015	SC 13D/A
Mar 15, 2024	chancellor michael b	20.0%	1,543,803	SC 13D/A
Mar 06, 2024	chancellor michael b	18.9%	1,398,897	SC 13D/A
Mar 06, 2024	kaufman jonathan h	18.3%	1,355,109	SC 13D/A
Feb 07, 2024	gruber michele	5.5%	365,000	SC 13G/A
Jan 25, 2024	huang leaf	9.6%	555,556	SC 13G/A
Jan 03, 2024	sabby management, llc	9.99%	579,814	SC 13G

Recent SEC filings of Lipella Pharmaceuticals Inc.

View All Filings

Date Filed	Form Type	Document
Apr 19, 2024	8-K	Current Report
Apr 12, 2024	8-K	Current Report
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	4	Insider Trading

Peers (Alternatives to Lipella Pharmaceuticals Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.1B	6.8B	3.52%	-17.31%	-8.94	6.15	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-3.68%	-28.69%	-41.18	9.92	76.23%	61.08%
BMRN	15.3B	2.5B	-7.53%	-16.73%	74.64	6.2	13.74%	186.89%
INCY	11.7B	3.8B	-8.64%	-30.91%	15.68	3.1	8.58%	129.81%
MID-CAP
APLS	5.3B	396.6M	-24.84%	-46.72%	-10.08	13.43	425.83%	18.94%
BBIO	4.5B	-	-17.14%	78.66%	-6.9	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.57%	4.22%	-14.61	12.91	440.80%	-27.84%
ARWR	2.8B	240.7M	-20.91%	-36.67%	-9.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-9.63%	-23.17%	-44.93	3.79	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-5.58%	-11.16%	24.84	4.45	85.90%	-14.05%
NVAX	606.0M	983.7M	-9.41%	-43.91%	-1.11	0.62	-50.36%	17.16%
CRBP	388.7M	881.7K	-5.61%	336.79%	-8.71	466.16	-77.61%	-5.33%
INO	267.6M	4.9M	-17.51%	25.55%	-1.98	54.99	-54.97%	51.71%
IBIO	6.0M	2.1M	-57.88%	56.88%	-0.22	2.14	-13.45%	66.37%

Lipella Pharmaceuticals Inc. News

Latest updates

Lipella Pharmaceuticals Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Revenue	16.1%	120,842	104,051	106,676	118,048	151,007	-	-	33,149	-
Operating Expenses	-41.8%	850,436	1,460,778	1,681,876	1,202,480	510,269	712,642	781,147	769,812	-
S&GA Expenses	-36.9%	396,236	627,518	624,231	508,750	32,167	61,688	38,487	93,850	-
R&D Expenses	-45.5%	454,201	833,260	1,057,645	693,730	478,102	650,954	742,660	675,962	-
EBITDA Margin	-Infinity%	-10.25	-	-9.76	-10.83	-14.05	-	-	-	-
Interest Expenses	-	-	-	5,454	5,394	4,705	1,653	1,636	1,618	-
Earnings Before Taxes	48.0%	-688,884	-1,323,570	-1,538,686	-1,067,825	-363,924	-713,794	-782,024	-737,950	-
EBT Margin	-14.8%	-10.27	-8.95	-9.81	-10.88	-14.11	-9.19	-8.41	-7.76	-7.19
Net Income	48.0%	-688,884	-1,323,570	-1,538,686	-1,067,825	-363,924	-713,794	-782,024	-737,950	-
Net Income Margin	-14.8%	-10.27	-8.95	-9.81	-10.88	-14.11	-9.19	-8.41	-7.76	-7.19
Free Cashflow	-Infinity%	-727,710	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet						(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2021Q4
Assets	25.9%	3,577	2,841	3,490	4,615	5,950	2,013
Current Assets	28.4%	3,429	2,671	3,367	4,478	5,799	1,808
Cash Equivalents	36.7%	3,294	2,410	3,114	4,019	5,122	1,414
Net PPE	-5.4%	13.00	13.00	-	-	-	-
Liabilities	-30.1%	433	619	364	798	1,275	589
Current Liabilities	-29.8%	385	549	299	717	1,178	341
Shareholder's Equity	41.5%	3,144	2,222	3,125	3,816	4,676	1,424
Retained Earnings	-7.1%	-10,323	-9,634	-8,311	-6,772	-5,704	-3,107
Additional Paid-In Capital	13.6%	13,468	11,856	11,436	10,589	10,380	4,530
Accumulated Depreciation	0.6%	128	127	-	-	126	-
Shares Outstanding	4.3%	6,054	5,804	5,744	5,744	5,744	3,867
Float	-	-	-	9,608	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)									(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Cashflow From Operations	-5.6%	-727	-689	-655	-1,077	-231	-320	-579	-699	-
Cashflow From Investing	-	-	-	-	-	-	-	601	-300	-
Cashflow From Financing	-	1,612	-	-250	-25.00	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LIPO Income Statement

2023-12-31

Statements of Operations - USD ($)	12 Months Ended
Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Total revenues	$ 449,617	$ 184,156
Cost and expenses
Research and development	3,038,836	2,547,677
General and administrative	2,156,734	226,192
Total costs and expenses	5,195,570	2,773,869
Loss from operations	(4,745,953)	(2,589,713)
Other income (expense)
Other income		(45)
Interest income	137,836	1,678
Interest expense related party	(10,848)	(9,612)
Total other income/(expense)	126,988	(7,979)
Loss before income taxes	(4,618,965)	(2,597,692)
Provision for income taxes
Net Loss	$ (4,618,965)	$ (2,597,692)
Loss per share of Common Stock
Basic	$ (0.77)	$ (0.64)
Dilutive	$ (0.77)	$ (0.64)
Weighted-average shares of Common Stock outstanding:
Basic	6,003,074	4,060,624
Dilutive	6,003,074	4,060,624
Grantrevenues [Member]
Total revenues	$ 449,617	$ 184,156
Contractrevenues [Member]
Total revenues

LIPO Balance Sheet

2023-12-31

Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 3,293,738	$ 5,121,743
Grants receivable	32,286	113,655
Prepaid expenses	103,256	563,891
Total Current Assets	3,429,280	5,799,289
Property and Equipment
Furniture, fixtures and equipment	140,294	125,859
Furniture, fixtures and equipment (Accumulated Depreciation)	(127,544)	(125,859)
Furniture and fixtures, net	12,750
Other Assets
Operating lease right of use asset	135,144	150,821
Total Other Assets	135,144	150,821
Total Assets	3,577,174	5,950,110
Current liabilities
Accounts payable	138,016	384,357
Accrued expenses	77,280	389,209
Operating lease liability	89,223	58,262
Payroll liability	80,836	67,832
Notes payable, current		25,000
Related party loan		250,000
Related party interest		3,596
Total Current Liabilities	385,355	1,178,256
Operating lease liability, net of current portion	47,371	96,258
Total Liabilities	432,726	1,274,514
Stockholders’ equity:
Preferred stock, $.0001 par value; 20,000,000 shares authorized; -0- shares issued and outstanding at December 31, 2023 and December 31, 2022
Common stock, $.0001 par value; 200,000,000 shares authorized; 6,053,956 shares issued and outstanding at December 31, 2023 and 5,743,956 at December 31, 2022	605	574
Additional paid-in capital*	13,467,686	10,379,900
Accumulated deficit	(10,323,843)	(5,704,878)
Total stockholders’ equity	3,144,448	4,675,596
Total liabilities and stockholders’ equity	$ 3,577,174	$ 5,950,110

About Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

CEO	Dr. Jonathan Kaufman M.B.A., Ph.D.
WEBSITE	lipella.com
INDUSTRY	Biotechnology
EMPLOYEES	5

Lipella Pharmaceuticals Inc. Frequently Asked Questions

What is the ticker symbol for Lipella Pharmaceuticals Inc.? What does LIPO stand for in stocks?

LIPO is the stock ticker symbol of Lipella Pharmaceuticals Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Lipella Pharmaceuticals Inc. (LIPO)?

As of Tue Apr 30 2024, market cap of Lipella Pharmaceuticals Inc. is 4.56 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LIPO stock?

You can check LIPO's fair value in chart for subscribers.

What is the fair value of LIPO stock?

You can check LIPO's fair value in chart for subscribers. The fair value of Lipella Pharmaceuticals Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Lipella Pharmaceuticals Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LIPO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Lipella Pharmaceuticals Inc. a good stock to buy?

The fair value guage provides a quick view whether LIPO is over valued or under valued. Whether Lipella Pharmaceuticals Inc. is cheap or expensive depends on the assumptions which impact Lipella Pharmaceuticals Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LIPO.

What is Lipella Pharmaceuticals Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, LIPO's PE ratio (Price to Earnings) is -0.99 and Price to Sales (PS) ratio is 10.15. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LIPO PE ratio will change depending on the future growth rate expectations of investors.